Goldman Sachs initiated coverage of Edwards Lifesciences with a Buy rating and $107 price target. The firm’s U.S. demographic analysis projects accelerating growth in the patient population most eligible for TAVR. It sees positive contribution from Edwards’ new technologies, like transcatheter mitral and tricuspid valves, in addition to incremental contribution from expanded TAVR indications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Shopify, Kraft Heinz upgraded: Wall Street’s top analyst calls
- Edwards Lifesciences upgraded to Buy from Neutral at Citi
- Roblox downgraded, Western Digital initiated: Wall Street’s top analyst calls
- Edwards Lifesciences upgraded to Buy from Hold at Deutsche Bank
- Edwards Lifesciences launches SAPIEN 3 Ultra RESILIA valve